San Diego-based mostly Viking Therapeutics marked itself as a serious competitor during the weight loss drug current market in February right after revealing promising details from the mid-phase trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when provided being a weekly injection and in March